From the publishers of JADPRO

MPN Resource Center

Advertisement
Advertisement
FROM THE EDITOR

Welcome to the JADPRO MPN Resource Center! We’ve expanded our previous platform to provide you more information, education, and cutting-edge research from the field of myeloproliferative neoplasms. We’re excited to provide this expanded offering to you and your colleagues. Take a look around, and send us your feedback to editor@advancedpractitioner.com

Lindsey Lyle, MS, PA-C                          Rocky Mountain Cancer Center 

 

 

News & Literature Highlights

Journal of Clinical Oncology

Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients

ASCO Abstract

MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor

Journal of Clinical Oncology

An open-label, multicenter, phase 1b/2 study of navtemadlin (KRT-232) in patients with relapsed/refractory acute myeloid leukemia secondary to myeloproliferative neoplasms

Journal of Clinical Oncology

Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study

International Journal of Hematology

Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives

JMIR Formative Research

Mobile app intervention on reducing the myeloproliferative neoplasm symptom burden: pilot feasibility and acceptability study

Therapeutic Advances in Hematology

A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study

Annals of Hematology

Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group

Scientific Reports

Potential limitations of diagnostic standard codes to distinguish polycythemia vera and secondary erythrocytosis

Korean Journal of Internal Medicine

How myeloproliferative neoplasms patients’ experience and expectations differ from physicians’: the international MPN Landmark survey

Advertisement
Advertisement